Swiss drug major Roche (SIX: ROG) said yesterday that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.
The drug is being developed by Roche’s Genentech subsidiary and uses USA-based Curis' (Nasdaq: CRIS) Hedgehog signaling pathway technology. Shares of Curis, which is eligible for regulatory milestones and royalties on eventual sales of the drug, leapt 17% to $3.44 in Monday morning trading. Roche anticipates making at least one regulatory submission in 2011 on the drug, potential revenue from which for this indication is expected to be below $500 million if approved.
The study met its primary endpoint (overall response rate), of showing vismodegib shrank tumors in a pre-defined percentage of people in the study. A preliminary safety assessment showed the most common adverse events were consistent with previous experience with vismodegib. A detailed safety assessment is ongoing, said Roche.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze